PMID- 36878815
OWN - NLM
STAT- MEDLINE
DCOM- 20230619
LR  - 20230619
IS  - 2090-2387 (Electronic)
IS  - 1687-1979 (Linking)
VI  - 24
IP  - 2
DP  - 2023 May
TI  - The role of mosapride and levosulpiride in gut function and glycemic control in 
      diabetic rats.
PG  - 109-116
LID - S1687-1979(23)00009-6 [pii]
LID - 10.1016/j.ajg.2023.01.008 [doi]
AB  - BACKGROUND AND STUDY AIMS: Gastroparesis is a well-known consequence of 
      long-standing diabetes that presents with gastric dysmotility in the absence of 
      gastric outlet obstruction. This study aimed to evaluate the therapeutic effects 
      of mosapride and levosulpiride on improving gastric emptying in type 2 diabetes 
      mellitus (T2DM) while regulating glycemic levels. MATERIAL AND METHODS: Rats were 
      divided into the normal control, untreated diabetic, metformin-treated 
      (100 mg/kg/day), mosapride-treated (3 mg/kg/day), levosulpiride-treated 
      (5 mg/kg/day), metformin (100 mg/kg/day) + mosapride (3 mg/kg/day)-treated, and 
      metformin (100 mg/kg/day) + levosulpiride (5 mg/kg/day)-treated diabetic groups. 
      T2DM was induced by a streptozotocin-nicotinamide model. Fourweeks from diabetes 
      onset, the treatment was started orally daily for 2 weeks. Serum glucose, 
      insulin, and glucagon-like peptide 1 (GLP-1) levels were measured. Gastric 
      motility study was performed using isolated rat fundus and pylorus strip 
      preparations. Moreover, the intestinal transit rate was measured. RESULTS: 
      Mosapride and levosulpiride administration showed a significant decrease in serum 
      glucose levels with improvement of gastric motility and intestinal transit rate. 
      Mosapride showed a significant increase in serum insulin and GLP-1 levels. 
      Metformin with mosapride and levosulpiride co-administration showed better 
      glycemic control and gastric emptying than either drug administered alone. 
      CONCLUSION: Mosapride and levosulpiride showed comparable prokinetic effects. 
      Metformin administration with mosapride and levosulpiride showed better glycemic 
      control and prokinetic effects. Mosapride provided better glycemic control than 
      levosulpiride. Metformin + mosapride combination provided superior glycemic 
      control and prokinetic effects.
CI  - Copyright (c) 2023 Pan-Arab Association of Gastroenterology. Published by Elsevier 
      B.V. All rights reserved.
FAU - Akrab, Sara N A
AU  - Akrab SNA
AD  - Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Egypt. 
      Electronic address: Sarah.Akrab@cu.edu.eg.
FAU - Al Gawhary, Nawal E
AU  - Al Gawhary NE
AD  - Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Egypt. 
      Electronic address: Nawal.Elgohary@kasralainy.edu.eg.
FAU - Shafik, Amani N
AU  - Shafik AN
AD  - Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Egypt. 
      Electronic address: amaninabil@cu.edu.eg.
FAU - Morcos, George N B
AU  - Morcos GNB
AD  - Department of Medical Biochemistry & Molecular Biology, Faculty of Medicine, 
      Cairo University, Egypt; Basic Medical Science Department, Faculty of Medicine, 
      King Salman International University, South Sinai, Egypt. Electronic address: 
      George.morcos@kasralainy.edu.eg.
FAU - Wissa, Marian Y
AU  - Wissa MY
AD  - Department of Medical Pharmacology, Faculty of Medicine, Cairo University, Egypt. 
      Electronic address: marianw780@cu.edu.eg.
LA  - eng
PT  - Journal Article
DEP - 20230304
PL  - Egypt
TA  - Arab J Gastroenterol
JT  - Arab journal of gastroenterology : the official publication of the Pan-Arab 
      Association of Gastroenterology
JID - 101298363
RN  - JTG7R315LK (levosulpiride)
RN  - I8MFJ1C0BY (mosapride)
RN  - 0 (Blood Glucose)
RN  - 9100L32L2N (Metformin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 0 (Insulins)
SB  - IM
MH  - Rats
MH  - Animals
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - Glycemic Control
MH  - Blood Glucose
MH  - *Gastroparesis/drug therapy
MH  - *Metformin/pharmacology/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - *Insulins/therapeutic use
OTO - NOTNLM
OT  - Gastroparesis
OT  - Insulin
OT  - Levosulpiride
OT  - Metformin
OT  - Mosapride
COIS- Declaration of competing interests The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/03/07 06:00
MHDA- 2023/06/19 13:08
CRDT- 2023/03/06 22:01
PHST- 2022/06/10 00:00 [received]
PHST- 2022/11/11 00:00 [revised]
PHST- 2023/01/17 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/06 22:01 [entrez]
AID - S1687-1979(23)00009-6 [pii]
AID - 10.1016/j.ajg.2023.01.008 [doi]
PST - ppublish
SO  - Arab J Gastroenterol. 2023 May;24(2):109-116. doi: 10.1016/j.ajg.2023.01.008. 
      Epub 2023 Mar 4.